Meeting
2019 ASCO Annual Meeting
A population-based model for predicting sentinel lymph node (SLN) status for cutaneous melanoma patients and a clinical decision rule (CDR) for sparing a SLN biopsy (SLNB).
Authors
Phyllis A. Gimotty
Univ of Pennsylvania School of Medcn, Philadelphia, PA
Phyllis A. Gimotty , Giorgos Karakousis , Meghan A. Buckley , DuPont Guerry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9589)
DOI
10.1200/JCO.2019.37.15_suppl.9589
Abstract #
9589
Poster Bd #
160
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Persistent poverty impacts survival and National Comprehensive Cancer Network guideline-concordant care for patients with melanoma.
First Author: Hayley Marie Dunlop
Poster
2023 ASCO Annual Meeting
Population-based validation of the Melanoma Institute Australia (MIA) and the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive tool for sentinel node status in patients with melanoma.
First Author: Rasmus Mikiver
Poster
2023 ASCO Annual Meeting
Integrating the 31-gene expression profile test into clinical decision-making to guide risk-aligned care decisions for patients with stage I-III cutaneous melanoma: NCI-SEER Analysis.
First Author: David Hyams
Poster
2023 ASCO Annual Meeting
Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected stage II/III melanoma.
First Author: Revathi Kollipara